{
    "clinical_study": {
        "@rank": "33657", 
        "arm_group": [
            {
                "arm_group_label": "1; liquid formulation", 
                "arm_group_type": "Active Comparator", 
                "description": "liquid formulation"
            }, 
            {
                "arm_group_label": "2; tablet formulation", 
                "arm_group_type": "Active Comparator", 
                "description": "tablet formulation"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare subject response to liquid vs. tablet formulations,\n      to assess bioequivalency of liquid vs. tablet, to compare subject preference, and to\n      evaluate if dose response curve for tablet is equal to liquid form.\""
        }, 
        "brief_title": "Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1", 
        "completion_date": {
            "#text": "August 1999", 
            "@type": "Actual"
        }, 
        "condition": "Opioid-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Opioid-Related Disorders"
        }, 
        "detailed_description": {
            "textblock": "1) Compare subjects response to liquid vs tablet formulation 2) Assess bioequivalency of\n      liquid vs tablet 3)Compare subject preference 4) Evaluate if dose response curve for tablet\n      = to liquid form"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        M/F ages 18-65. Meet DMS-IV criteria for opiate dependence. Agree to conditions of the\n        study and sign informed consent.\n\n        Exclusion Criteria:\n\n        Pregnant or nursing women. Acute medical condition that would interfere with study\n        participation or put safety of subjects in jeopardy. Current daily use of\n        anti-convulsants, antabuse or neuroleptics. DSM-IV diagnosis of ETOH or sedative/hypnotics\n        dependence."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 20, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000320", 
            "org_study_id": "NIDA-10068-1", 
            "secondary_id": "R01-10068-1"
        }, 
        "intervention": {
            "arm_group_label": [
                "1; liquid formulation", 
                "2; tablet formulation"
            ], 
            "description": "random assignment to liquid buprenorphine or tablet buprenorphine", 
            "intervention_name": "Buprenorphine formulation: liquid vs. tablet", 
            "intervention_type": "Drug", 
            "other_name": [
                "Subutex", 
                "Suboxone"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Buprenorphine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 5, 2009", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90025"
                }, 
                "name": "Friends Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution", 
        "overall_official": {
            "affiliation": "Friends Research Institute, Inc.", 
            "last_name": "Walter Ling, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 1999", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "blood level", 
            "safety_issue": "Yes", 
            "time_frame": "across study duration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000320"
        }, 
        "responsible_party": {
            "name_title": "Walter Ling, M.D.", 
            "organization": "Friends Research Institute"
        }, 
        "secondary_outcome": [
            {
                "measure": "drug use", 
                "safety_issue": "Yes", 
                "time_frame": "across study duration"
            }, 
            {
                "measure": "craving", 
                "safety_issue": "Yes", 
                "time_frame": "across study duration"
            }, 
            {
                "measure": "withdrawal symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "across study duration"
            }
        ], 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 1997", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2009"
    }, 
    "geocoordinates": {
        "Friends Research Institute": "34.052 -118.244"
    }
}